Overview
CervoMed Q3 2025 net loss of $7.7 mln misses analyst expectations
Cash position decreased to $27.3 mln as of September 30, 2025
Outlook
CervoMed plans to initiate a global pivotal Phase 3 trial in DLB in H2 2026
Company expects initial biomarker data from Phase 2a FTD trial in 2026
CervoMed aligned with FDA on Phase 3 trial design for neflamapimod in DLB
Result Drivers
CASH POSITION - As of September 30, CervoMed had 27.3 mln in cash, cash equivalents, and marketable securities vs $38.9 mln as of December 31
OPERATING PLAN - CervoMed believes its cash will fund operations into Q3 2026
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
Miss
-$7.70 mln
-$6.33 mln (5 Analysts)
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CervoMed Inc is $20.00, about 65.4% above its November 7 closing price of $6.92
Press Release: ID:nGNX3MgWQc
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
